Results 31 to 40 of about 106,290 (280)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions

Allergology International
Background: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock.
Hung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, Tsai-Sheng Yang, John Wen-Cheng Chang, Chia-Hsun Hsieh, Shuen-Iu Hung, Chun-Wei Lu, Jen-Shi Chen, Wen-Chi Chou, Chuang-Wei Wang   +10 more
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer

Pharmaceuticals
Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism was proposed.
Xiaoqing Wang, Meili Xi, Xing Lu, Xiangshi Tan   +3 more
doaj   +1 more source

Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1.

PLoS ONE, 2014
BackgroundEvidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is ...
Yang Bu, Qing-An Jia, Zheng-Gang Ren, Ju-Bo Zhang, Xue-Mei Jiang, Lei Liang, Tong-Chun Xue, Quan-Bao Zhang, Yan-Hong Wang, Lan Zhang, Xiao-Ying Xie, Zhao-You Tang   +11 more
doaj   +1 more source

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer [PDF]

, 2007
Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in
Boeck, Stefan, Bruns, Christiane J., Golf, Alexander, Haas, Michael, Heinemann, Volker, Issels, Rolf-Dieter, Laessig, Dorit, Moosmann, Nicolas, Schulz, Christoph, Wilkowski, Ralf   +9 more
core   +1 more source

Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature

Journal of Hematology & Oncology, 2010
Background Oxaliplatin is a platinum compound used in the treatment of gastrointestinal malignancies, including colorectal cancer. The incidence of hypersensitivity reaction in patients receiving oxaliplatin is approximately 15%, with severe reaction ...
Aster Richard H, Curtis Brian R, Chen Chien-Shing, Stevens W, Bautista Marnelli A, Hsueh Chung-Tsen   +5 more
doaj   +1 more source

Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases [PDF]

, 2002
Background: The management of recurrent, metastatic cholangiocarcinoma still remains a problem since this tumor entity is classified as chemotherapy-resistant.
Heinemann, Volker, Schalhorn, A., Stemmler, Joachim   +2 more
core   +1 more source

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. [PDF]

, 2015
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer.
Herman, June, Kain, Tatiana, Seery, Tara, Tang, Ronald   +3 more
core   +3 more sources